再鼎医药有限公司近日公布了2024年第四季度及全年财务业绩。数据显示,2024年第四季度产品收入净额达到1.085亿美元,较2023年同期的6,580万美元大幅增长。全年产品收入净额为3.976亿美元,相比2023年的2.667亿美元也有显著提升。收入增长主要得益于卫伟迦销量的提升,以及则乐和纽再乐的销量增长。尽管产品收入增长显著,再鼎医药在2024年第四季度仍录得8,170万美元的亏损净额,全年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.